Regulatory posture
Ipamorelin is not FDA approved for any indication and has no marketing authorization in the United States. It was investigated for postoperative ileus but did not reach approval, and it is not an established compounding candidate under current FDA positions on peptide compounding. It is not scheduled by the DEA, but it is prohibited in sport by the World Anti-Doping Agency.
Mechanism, plain English
Ipamorelin acts like ghrelin, a natural hunger and growth hormone signaling molecule, by turning on the growth hormone secretagogue receptor. This prompts the pituitary gland to release growth hormone in a selective way, with less effect on other hormones such as cortisol. The intended result is a pulse of growth hormone similar to the body's own pattern.
Evidence landscape
Ipamorelin has clear early pharmacology data but limited evidence of clinical benefit. It was first described as a selective growth hormone secretagogue that raises growth hormone with minimal effect on other pituitary hormones in preclinical work. A human pharmacokinetic and pharmacodynamic study confirmed that it stimulates growth hormone release in volunteers. A Phase 2 randomized controlled trial tested ipamorelin for postoperative ileus after bowel resection and did not demonstrate the intended benefit, and the program did not advance to approval. The literature confirms that ipamorelin can raise growth hormone but does not support established clinical efficacy or long-term safety in humans.
Primary PubMed citations
- Ipamorelin, the first selective growth hormone secretagogue , Raun K et al, European Journal of Endocrinology, 1998. PMID: 9849822
- Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers , Gobburu JV et al, Pharmaceutical Research, 1999. PMID: 10496658
- Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients , Beck DE et al, International Journal of Colorectal Disease, 2014. PMID: 25331030
Citations selected from the PubMed literature. Every URL was checked at publication time. Scriptura's daily PubMed scan surfaces new studies for each compound as they index. See the regulatory and literature layers on the demo.
This is a plain English summary of the peer reviewed literature and current regulatory posture. It is not a substitute for a licensed clinician's judgment on a specific patient. It does not recommend dosing, cadence, or route. Where the literature is limited or preclinical, this page says so, so a prescriber can weigh marketing claims against what the trials actually show.